MedTrace Logo

Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients

NCT06137690 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2024-02-16

No results posted yet for this study

Summary

This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from July 2018 to June 2023. The initial voriconazole serum trough concentration, Correlation of various factors, and risk prediction factors for voriconazole serum trough concentration and hepatotoxicity were compared between elderly and non-elderly patients.

Conditions

  • Invasive Fungal Infection

Interventions

DEVICE

other antifungal agents,breathing machine

If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Sponsors & Collaborators

  • People's Hospital of Zhengzhou University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
98 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137690 on ClinicalTrials.gov